Halozyme Therapeutics (HALO) Long-Term Deferred Tax (2021 - 2025)

Halozyme Therapeutics (HALO) has 5 years of Long-Term Deferred Tax data on file, last reported at $20.2 million in Q2 2025.

• Long-Term Deferred Tax for Q2 2025 came in at $20.2 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2025 was $20.2 million (changed N/A YoY), and the FY2024 annual result was $3.9 million, down 12.11% from the prior year.
• Long-Term Deferred Tax rose to $20.2 million in Q2 2025 per HALO's latest filing, from $5.2 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $155.4 million in Q4 2021 and troughed at $616000.0 in Q1 2024.
• A 5-year average of $49.3 million and a median of $22.1 million in 2023 frame the typical range for Long-Term Deferred Tax.
• The sharpest annual moves came in 2024 and 2025: Long-Term Deferred Tax tumbled 98.27% in 2024, then soared 742.53% in 2025.
• A 5-year view of Long-Term Deferred Tax shows it stood at $155.4 million in 2021, then tumbled by 71.42% to $44.4 million in 2022, then plunged by 90.13% to $4.4 million in 2023, then retreated by 12.11% to $3.9 million in 2024, then jumped by 424.2% to $20.2 million in 2025.
• Business Quant data shows HALO's Long-Term Deferred Tax at $20.2 million in Q2 2025, $5.2 million in Q1 2025, and $3.9 million in Q4 2024.